1
|
Gray B, Lubbock K, Love C, Ryder E, Hudson S, Scarth J. Analytical advances in horseracing medication and doping control from 2018 to 2023. Drug Test Anal 2024. [PMID: 39010718 DOI: 10.1002/dta.3760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2024] [Revised: 06/07/2024] [Accepted: 06/20/2024] [Indexed: 07/17/2024]
Abstract
The analytical approaches taken by laboratories to implement robust and efficient regulation of horseracing medication and doping control are complex and constantly evolving. Each laboratory's approach will be dictated by differences in regulatory, economic and scientific drivers specific to their local environment. However, in general, laboratories will all be undertaking developments and improvements to their screening strategies in order to meet new and emerging threats as well as provide improved service to their customers. In this paper, the published analytical advances in horseracing medication and doping control since the 22nd International Conference of Racing Analysts and Veterinarians will be reviewed. Due to the unprecedented impact of COVID-19 on the worldwide economy, the normal 2-year period of this review was extended to over 5 years. As such, there was considerable ground to cover, resulting in an increase in the number of relevant publications included from 107 to 307. Major trends in publications will be summarised and possible future directions highlighted. This will cover developments in the detection of 'small' and 'large' molecule drugs, sample preparation procedures and the use of alternative matrices, instrumental advances/applications, drug metabolism and pharmacokinetics, the detection and prevalence of 'endogenous' compounds and biomarker and OMICs approaches. Particular emphasis will be given to research into the potential threat of gene doping, which is a significant area of new and continued research for many laboratories. Furthermore, developments in analytical instrumentation relevant to equine medication and doping control will be discussed.
Collapse
|
2
|
Klöppner L, Harps LC, Parr MK. Sample Preparation Techniques for Growth-Promoting Agents in Various Mammalian Specimen Preceding MS-Analytics. Molecules 2024; 29:330. [PMID: 38257243 PMCID: PMC10818438 DOI: 10.3390/molecules29020330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2023] [Revised: 12/24/2023] [Accepted: 01/01/2024] [Indexed: 01/24/2024] Open
Abstract
The misuse of growth-promoting drugs such as beta-2 agonists and steroids is a known problem in farming and sports competitions. Prior to the analysis of biological samples via liquid chromatography (LC)-mass spectrometry (MS) or gas chromatography (GC)-MS, sufficient sample preparation is required to reliably identify or determine the residues of drugs. In practice, broad screening methods are often used to save time and analyze as many compounds as possible. This review was conceptualized to analyze the literature from 2018 until October 2023 for sample preparation procedures applied to animal specimens before LC- or GC-MS analysis. The animals were either used in farming or sports. In the present review, solid phase extraction (SPE) was observed as the dominant sample clean-up technique for beta-2 agonists and steroids, followed by protein precipitation. For the extraction of beta-2 agonists, mixed-mode cation exchanger-based SPE phases were preferably applied, while for the steroids, various types of SPE materials were reported. Furthermore, dispersive SPE-based QuEChERs were utilized. Combinatory use of SPE and liquid-liquid extraction (LLE) was observed to cover further drug classes in addition to beta-2 agonists in broader screening methods.
Collapse
Affiliation(s)
| | | | - Maria Kristina Parr
- Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Straße 2+4, 14195 Berlin, Germany; (L.K.); (L.C.H.)
| |
Collapse
|
3
|
Cloteau C, Dervilly G, Loup B, Delcourt V, Kaabia Z, Bagilet F, Groseille G, Dauriac K, Fisher S, Popot MA, Garcia P, Le Bizec B, Bailly-Chouriberry L. Performance assessment of an equine metabolomics model for screening a range of anabolic agents. Metabolomics 2023; 19:38. [PMID: 37027080 DOI: 10.1007/s11306-023-01985-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Accepted: 03/04/2023] [Indexed: 04/08/2023]
Abstract
INTRODUCTION Despite their ban, Anabolic Androgenic Steroids (AAS) are considered as the most important threat for equine doping purposes. In the context of controlling such practices in horse racing, metabolomics has emerged as a promising alternative strategy to study the effect of a substance on metabolism and to discover new relevant biomarkers of effect. Based on the monitoring of 4 metabolomics derived candidate biomarkers in urine, a prediction model to screen for testosterone esters abuse was previously developed. The present work focuses on assessing the robustness of the associated method and define its scope of application. MATERIALS AND METHODS Several hundred urine samples were selected from 14 different horses of ethically approved administration studies involving various doping agents' (AAS, SARMS, β-agonists, SAID, NSAID) (328 urine samples). In addition, 553 urine samples from untreated horses of doping control population were included in the study. Samples were characterized with the previously described LC-HRMS/MS method, with the objective of assessing both its biological and analytical robustness. RESULTS The study concluded that the measurement of the 4 biomarkers involved in the model was fit for purpose. Further, the classification model confirmed its effectiveness in screening for testosterone esters use; and it demonstrated its ability to screen for the misuse of other anabolic agents, allowing the development of a global screening tool dedicated to this class of substances. Finally, the results were compared to a direct screening method targeting anabolic agents demonstrating complementary performances of traditional and omics approaches in the screening of anabolic agents in horses.
Collapse
Affiliation(s)
- C Cloteau
- LABERCA, ONIRIS, INRAE, 44300, Nantes, France.
- Laboratoire des Courses Hippiques (GIE-LCH), 91370, Verrières Le Buisson, France.
| | - G Dervilly
- LABERCA, ONIRIS, INRAE, 44300, Nantes, France
| | - B Loup
- Laboratoire des Courses Hippiques (GIE-LCH), 91370, Verrières Le Buisson, France
| | - V Delcourt
- Laboratoire des Courses Hippiques (GIE-LCH), 91370, Verrières Le Buisson, France
| | - Z Kaabia
- Laboratoire des Courses Hippiques (GIE-LCH), 91370, Verrières Le Buisson, France
| | - F Bagilet
- Laboratoire des Courses Hippiques (GIE-LCH), 91370, Verrières Le Buisson, France
| | - G Groseille
- Laboratoire des Courses Hippiques (GIE-LCH), 91370, Verrières Le Buisson, France
| | - K Dauriac
- Laboratoire des Courses Hippiques (GIE-LCH), 91370, Verrières Le Buisson, France
| | - S Fisher
- Laboratoire des Courses Hippiques (GIE-LCH), 91370, Verrières Le Buisson, France
| | - M A Popot
- Laboratoire des Courses Hippiques (GIE-LCH), 91370, Verrières Le Buisson, France
| | - P Garcia
- Laboratoire des Courses Hippiques (GIE-LCH), 91370, Verrières Le Buisson, France
| | - B Le Bizec
- LABERCA, ONIRIS, INRAE, 44300, Nantes, France
| | - L Bailly-Chouriberry
- Laboratoire des Courses Hippiques (GIE-LCH), 91370, Verrières Le Buisson, France
| |
Collapse
|
4
|
From targeted methods to metabolomics based strategies to screen for growth promoters misuse in horseracing and livestock: A review. Food Control 2023. [DOI: 10.1016/j.foodcont.2023.109601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
5
|
Purnama SK, Doewes RI, Elumalai G, Azmi SH, Nuryadin I, Manshuralhudlori. BIOSENSOR DEVELOPMENT IN SPORTS DOPING WITH DEXAMETHASONE. REV BRAS MED ESPORTE 2023. [DOI: 10.1590/1517-8692202329012022_0416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
ABSTRACT Introduction: Dexamethasone is a type of drug that is considered a steroid. It belongs to a class of drugs known as corticosteroids. Objective: Develop an electrochemical sensor of dexamethasone in a pharmaceutical sample using electrodes modified with nanostructures of MnO2 and reduced graphene oxide (MnO2/rGO). The glassy carbon electrodes (GCE) used to make the GO nanostructures were first modified using a modified Hummers technique before electrochemically reduced. Methods: MnO2 nanomaterials were electrochemically deposited on rGO/GCE. SEM structural investigation indicated vertical tetragonal crystal development of -MnO2 nanostructures in sprayed rGO nanostructures. Results: Because of the high composite surface area, multiple exposed active sites, and the synergistic effect of MnO2 and rGO, the electrocatalytic reaction to dexamethasone of MnO2/rGO/CPE was shown to be broad, selective, stable, and sensitive in electrochemical tests using amperometry. It was established that the linear range, sensitivities, and detection limit of the sensor are 0 to 260 µM, 4.6153µA/µM and 0.005 µM, respectively. The MnO2/rGO/CPE was tested for accuracy and applicability in determining dexamethasone in pharmacological and human urine samples. Conclusion: The results revealed that the sensor could prepare acceptable recovery (96.34%) and RSD (3.58%), suggesting that it could be used as a reliable dexamethasone sensor in clinical samples. Level of evidence II; Therapeutic studies - Investigation of treatment outcomes.
Collapse
Affiliation(s)
| | - Rumi Iqbal Doewes
- Sebelas Maret University, Indonesia; Universiti Pendidikan Sultan Idris, Malaysia
| | | | | | | | | |
Collapse
|
6
|
Marlier D. Doping in Racing Pigeons ( Columba livia domestica): A Review and Actual Situation in Belgium, a Leading Country in This Field. Vet Sci 2022; 9:42. [PMID: 35202294 PMCID: PMC8880243 DOI: 10.3390/vetsci9020042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Revised: 01/13/2022] [Accepted: 01/20/2022] [Indexed: 02/05/2023] Open
Abstract
Pigeon racing is a sport in which trained homing pigeons (Columba livia domestica) are released between 60 and 1200 km from their loft and then have to return home as quickly as possible. The first race was held in 1818 in Belgium and since then, Belgium has led the world in pigeon breeding. Unfortunately, as in other sports, doping has become a major issue and doping controls have been implemented. This review provides information about pigeon racing, rules from the Royal Federation Colombophile of Belgium, and laws applicable in Belgium as doping control issues cannot be understood without including them as part of pigeon racing. The main pharmacological data concerning corticoids, non-steroidal anti-inflammatory drugs, anabolic steroids, pain relievers and narcotic analgesics, bronchodilators and β-agonists, drugs acting on the central nervous system and other performance-enhancing drugs, in addition to methods relevant to doping in pigeons are presented. Moreover, the chosen matrix and analytical methods are described.
Collapse
Affiliation(s)
- Didier Marlier
- Bird, Rabbit and Rodent Clinic, Faculty of Veterinary Medicine, University of Liege, B4000 Liege, Belgium
| |
Collapse
|